Ueshima D, et al. - Researchers used a multicenter registry to determine the impact of overweight status (defined as body mass index > 25 kg/m²) on adverse events in patients who had everolimus-eluting stent (EES) implantation with a maximum follow-up of 3 years. They performed propensity score matching for adjusting baseline characteristics. They found that even when excluding non-cardiac mortalities, better outcomes for major adverse cardiac and cerebrovascular events (MACCE: a composite of mortality from all causes, nonfatal myocardial infarction, and nonfatal stroke) were demonstrated by overweight patients. With regard to secondary prevention of cardiovascular events, no advantage to non-overweight EES-implanted patients was seen.